Prosonix (Oxford, UK), an emerging pharmaceutical company developing a portfolio of enhanced respiratory medicines enabled by its novel proprietary particle engineering technology, is very pleased to announce that it has elected Dr Ken Cunningham to its Board of Directors as a Non-Executive Director and Chair of its Advisory Board.
Dr Cunningham has over 20 years’ experience in the pharmaceutical industry with a strong focus in recent years on respiratory drug development and drug delivery. He is Executive Chairman of PolyTherics Ltd and until August 2010 was CEO of Skyepharma plc. Before that he was Chief Executive Officer of Arakis Ltd, Vice-President European Affairs at Alza Corporation and Vice-President Clinical Development at Sequus Inc. Prior to this he held a variety of clinical development and commercial strategy roles at GlaxoWellcome plc and Warner-Lambert earlier in his career. Ken is also a Non-Executive Director of Xention Ltd. He holds a medical degree from St Mary’s, Imperial College, London University.
Commenting on the appointment, Jim Phillips, Prosonix’ Chairman, said: “We are very pleased to welcome Ken to the board at this exciting stage in the Company’s development. Ken brings a wealth of experience in respiratory drug development and we very much look forward to his strategic advice and input as we invest the proceeds from our recent £11.4 million fund raising to generate key performance and clinical data for our lead respiratory drug candidates.”
Ken Cunningham, said: “The global market for respiratory medicines is entering a period of transition as many leading blockbuster products approach the end of their patents. Complex manufacturing challenges mean that new products need to demonstrate significant performance advantages in order to take their place. Prosonix has the unique approach of developing respiratory medicines based on ‘smart’ particles whose fundamental properties are designed for delivery, using simple inhalation devices, to the parts of the respiratory system where they can elicit the optimal clinical effect. I am very much looking forward to working with the company during this exciting phase of its growth.”
Notes for Editors
About Prosonix www.prosonix.co.uk
Prosonix is an emerging pharmaceutical company developing a portfolio of enhanced respiratory medicines (mono and combination therapies) that could revolutionise the multi-billion dollar global market for inhaled therapies.
Its current development programmes include:
• a drug-only version of fluticasone propionate, a potent inhaled corticosteroid monotherapy for asthma in metered dose inhaler (MDI);
• a drug-only version of glycopyrrolate, a long acting muscarinic antagonist for COPD in MDI, and
• a potentially revolutionary approach to combination therapy
Prosonix’ pipeline is underpinned by its world leading expertise in pharmaceutical particle engineering and its unique, proprietary DISCUS® and UMAX® technologies. These capabilities enable Prosonix to develop ‘smart’ respiratory drug particles that are specifically designed to target the optimum site of action in the lung, precisely and consistently, to gain maximum clinical effect.
By controlling particle size, shape and form Prosonix can develop superior drug formulations, offering more accurate dosing and enabling the use of simple, cost-effective MDI and dry powder inhaler devices.
Prosonix raised £11.4 million in June 2011 from experienced life sciences investors including Ventech, Gilde Healthcare Partners, Enterpreneurs Fund, Quest for Growth and Solon Ventures.